baclofen

(redirected from Gablofen)
Also found in: Medical.
Related to Gablofen: Kemstro, Lioresal Intrathecal

bac·lo·fen

 (băk′lə-fĕn)
n.
A drug, C10H12ClNO2, that acts as a gamma-aminobutyric acid receptor agonist and is used to treat muscle spasticity, especially in patients with multiple sclerosis and spinal cord injuries.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

baclofen

(ˈbækləʊˌfɛn)
n
a muscle-relaxing drug used to treat muscle spasms
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
Translations

baclofen

n baclofeno
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
Hereinafter is a description of a woman with a recently implanted intrathecal pump with signs of withdrawal after refilling her pump with Gablofen.
The company's Intrathecal Therapy business markets products used in the treatment of spasticity via intrathecal drug delivery, including the key asset Gablofen (baclofen injection).
The key asset is Gablofen (baclofen injection), a product approved by the US Food and Drug Administration for use in management of severe spasticity of cerebral or spinal origin in adult and pediatric patients age 4 years and above.
The acquired products include drugs such as Gablofen for treatment of severe spasticity and two pain management drugs under development.
Food and Drug Administration has approved Covidien plc's Gablofen prefilled syringes.
According to the company, the Intrathecal Therapy business markets products for the treatment of spasticity via intrathecal drug delivery, including the key asset Gablofen (baclofen injection).
Included in the acquired portfolio is Gablofen (baclofen), a severe spasticity management drug that is currently marketed in the US.
The remaining total consideration of up to USD32m is contingent, based on the gross profit of the Gablofen products in 2018 and 2019.
Included in the portfolio is Gablofen (baclofen) -- a severe spasticity management product currently marketed in the US - and two pain management products that are under development.
M2 PHARMA-January 22, 2013-Mallinckrodt's new Gablofen prefilled syringe wins FDA approval to help simplify ITB refills in spastic patients(C)2013 M2 COMMUNICATIONS